Engineering the Future of Medicine: The Evolution of Monoclonal Antibody (mAb) Therapeutics
Background: Monoclonal antibodies (mAbs) have become one of the most successful classes of biopharmaceuticals, revolutionizing the treatment of cancer, autoimmune disorders, infectious diseases, and numerous chronic conditions. Since the introduction of hybridoma technology in 1975, continuous advances in antibody engi...